アミバンタマブとラゼルチニブで一次治療を受けた上皮成長因子受容体(EGRF)変異非小細胞肺がん(NSCLC)における発疹と爪囲炎を軽減するための皮膚科ケアの強化 (COCOON)
アミバンタマブ + ラゼルチニブで第一選択治療を受けた局所進行性または転移性 EGFR 変異 NSCLC 患者の選択された皮膚科学的有害事象に対する、強化された皮膚科学的管理と標準的な皮膚科学的管理の影響を評価する第 2 相非盲検ランダム化試験
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade >=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Chandler、Arizona、アメリカ、85224
- Ironwood Cancer and Research Center
-
-
California
-
Duarte、California、アメリカ、91010
- City of Hope
-
Fullerton、California、アメリカ、92835
- Providence Fullerton
-
Glendale、California、アメリカ、91204
- Los Angeles Cancer Network
-
Huntington Beach、California、アメリカ、92648
- City of Hope Seacliff
-
Irvine、California、アメリカ、92618
- City of Hope Orange County Lennar Foundation Cancer Center
-
Long Beach、California、アメリカ、90813
- City of Hope Long Beach Elm
-
Los Alamitos、California、アメリカ、90720
- Cancer and Blood Specialty Clinic
-
Los Angeles、California、アメリカ、90033
- Keck Hospital of USC
-
Newport Beach、California、アメリカ、92663
- USC Norris Oncology Hematology Newport Beach
-
Oakland、California、アメリカ、94611
- Kaiser Permanente Oakland Medical Center
-
Roseville、California、アメリカ、95661
- Kaiser Permanente Roseville Medical Center
-
San Francisco、California、アメリカ、94115
- Kaiser Permanente San Francisco Medical Center
-
Santa Clara、California、アメリカ、95051
- Kaiser Permanente Santa Clara Medical Center
-
South Pasadena、California、アメリカ、91030
- City of Hope South Pasadena
-
Vallejo、California、アメリカ、94589
- Kaiser Permanente Northern California
-
Walnut Creek、California、アメリカ、94596
- Kaiser Permanente Walnut Creek Medical Center
-
-
Georgia
-
Athens、Georgia、アメリカ、30607
- University Cancer & Blood Center
-
-
Illinois
-
Hinsdale、Illinois、アメリカ、60521
- Hope and Healing Care
-
-
Missouri
-
Springfield、Missouri、アメリカ、65807
- Oncology Hematology Associates
-
-
Nevada
-
Reno、Nevada、アメリカ、89502
- Renown Health Medical Oncology
-
-
New Jersey
-
Flemington、New Jersey、アメリカ、08822
- Hunterdon Hematology Oncology
-
-
New York
-
Westbury、New York、アメリカ、11590
- Clinical Research Alliance Inc
-
-
North Carolina
-
Wilson、North Carolina、アメリカ、27893
- Regional Medical Oncology Center
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- University Hospitals Cleveland Medical Center
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- Virginia Cancer Specialists
-
-
Washington
-
Renton、Washington、アメリカ、98055
- Valley Medical Center
-
-
Wisconsin
-
West Salem、Wisconsin、アメリカ、54669
- Gundersen Health System
-
-
-
-
-
Buenos Aires、アルゼンチン、C1199
- Hospital Italiano de Buenos Aires
-
CABA、アルゼンチン、C1122
- IADT Instituto Argentino de Diagnostico y Tratamiento
-
Capital Federal、アルゼンチン、C1017
- Centro Medico Austral
-
La Plata、アルゼンチン、B1900AXI
- Hospital Italiano de La Plata
-
Mar del Plata、アルゼンチン、B7602
- Hospital Privado de la Comunidad
-
-
-
-
-
A Coruña、スペイン、15006
- Hosp Univ A Coruna
-
Alicante、スペイン、03010
- Hosp. Gral. Univ. de Alicante
-
Barcelona、スペイン、08028
- Hosp. Univ. Quiron Dexeus
-
Barcelona、スペイン、08035
- Hosp Univ Vall D Hebron
-
Jaén、スペイン、23007
- Hosp. Univ. de Jaen
-
Lugo、スペイン、27003
- Hosp. Univ. Lucus Augusti
-
Madrid、スペイン、28007
- Hosp. Gral. Univ. Gregorio Maranon
-
Málaga、スペイン、29010
- Hosp Regional Univ de Malaga
-
Seville、スペイン、41014
- Hosp. Ntra. Sra. de Valme
-
-
-
-
-
Adana、トルコ(Türkiye)、1060
- Adana City Hospital
-
Ankara、トルコ(Türkiye)、06560
- Gazi University Hospital
-
Ankara、トルコ(Türkiye)、06010
- Gulhane Training and Research Hospital
-
Ankara、トルコ(Türkiye)、6800
- Ankara Bilkent City Hospital
-
Istanbul、トルコ(Türkiye)、34147
- Bakirkoy Training and Research Hospital
-
Istanbul、トルコ(Türkiye)、34295
- I A U VM Medical Park Florya Hastanesi
-
Izmir、トルコ(Türkiye)、35100
- Ege University Medical Faculty
-
Samsun、トルコ(Türkiye)、55420
- Ondokuz Mayis University
-
-
-
-
-
Aachen、ドイツ、52074
- Universitaetsklinikum der RWTH Aachen
-
Essen、ドイツ、45136
- Kliniken Essen-Mitte
-
Giessen、ドイツ、35392
- Universitaetsklinikum Giessen und Marburg GmbH
-
Heidelberg、ドイツ、69126
- Thoraxklinik am Universitatsklinikum Heidelberg
-
Kassel、ドイツ、34125
- Klinikum Kassel GmbH
-
Kiel、ドイツ、24105
- Universitaetsklinikum Schleswig Holstein Campus Kiel
-
-
-
-
-
Marseille、フランス、13915
- Hopital Nord
-
Nice、フランス、06001
- Hopital PASTEUR
-
Paris、フランス、75005
- Institut Curie
-
-
-
-
-
Belo Horizonte、ブラジル、30150-221
- Santa Casa de Misericordia de Belo Horizonte
-
Belém、ブラジル、66.073-005
- CTO Centro De Tratamento Oncologico LTDA
-
Curitiba、ブラジル、81520-060
- Liga Paranaense de Combate ao Cancer
-
Jaú、ブラジル、17.210-080
- Fundacao Doutor Amaral Carvalho
-
Porto Alegre、ブラジル、91350 200
- Hospital Nossa Senhora da Conceicao S A
-
Salvador、ブラジル、40170 070
- Nucleo de Oncologia da Bahia Oncoclinicas
-
Santa Cruz do Sul、ブラジル、96835-100
- Hospital Ana Nery Santa Cruz do Sul
-
São Paulo、ブラジル、01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、ブラジル、01246 000
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
Taubaté、ブラジル、12030-200
- Servicos de Tratamento ao Cancer de Taubate LTDA - Instituto do Cancer Brasil Unidade Taubate
-
Vitória、ブラジル、29043-260
- Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia
-
-
-
-
-
George Town、マレーシア、10450
- Hospital Pulau Pinang
-
Kuala Lumpur、マレーシア、59100
- University Malaya Medical Centre
-
Kuantan、マレーシア、25100
- Hospital Tengku Ampuan Afzan
-
Kuching、マレーシア、93586
- Hospital Umum Sarawak
-
-
-
-
-
Changzhou、中国、213004
- Changzhou No 2 Peoples Hospital
-
Chengdoucun、中国、610041
- West China Hospital
-
Chengdu、中国、610041
- Sichuan Cancer Hospital
-
Guangzhou、中国、510080
- The First Affiliated Hospital Sun Yat sen University
-
Hangzhou、中国、310003
- The First Affiliated Hospital Zhejiang University School of Medicine
-
Harbin、中国、150040
- Harbin medical university cancer hospital
-
Huizhou、中国、516001
- Huizhou Municipal Central Hospital
-
Nanjing、中国、210000
- Zhongda Hospital Southeast University
-
Shanghai、中国、200032
- Fudan University Shanghai Cancer Center
-
Xi'an、中国、710061
- The First Affiliated Hospital of Xian Jiaotong University
-
Zhengzhou、中国、450008
- Henan Cancer Hospital
-
-
-
-
-
Hsinchu、台湾、30059
- National Taiwan University Hospital Hsin Chu Branch
-
Kaohsiung City、台湾、833
- Chang Gung Memorial Hospital
-
Taichung、台湾、40705
- Taichung Veterans General Hospital
-
Taipei、台湾、100
- National Taiwan University Hospital
-
Taoyuan City、台湾、333
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Cheongju-si、韓国、28644
- Chungbuk National University Hospital
-
Incheon、韓国、21565
- Gachon University Gil Medical Center
-
Seoul、韓国、03722
- Severance Hospital Yonsei University Health System
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC); Is treatment naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for Stage I, Stage II or Stage IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease
- Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States) in accordance with site standard-of-care
- A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants with a history of symptomatic brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization, and the participant can be receiving no greater than 10 milligram (mg) prednisone or equivalent daily for the treatment of intracranial disease
- Can have prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s). For the amivantamab SC expansion cohorts: Due to the increased risk of skin cancer with ruxolitinib, participants with any prior or concurrent skin malignancies will be excluded
- Sub-study: Participants must have new-onset or persistent (defined as non-responsive to standard of care [SoC]) Grade >=2 specific DAEIs of the scalp, face, or body, as defined by NCI-CTCAE Grading v5.0 for DAEIs (excluding paronychia)
Exclusion Criteria:
- History of uncontrolled illness, including but not limited to uncontrolled diabetes; ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to starting background anticancer treatment] or diagnosed or suspected viral infection). For the amivantamab SC expansion cohorts, this includes active localized serious infections; active bleeding diathesis; impaired oxygenation requiring continuous oxygen supplementation; refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of background anticancer treatment or doxycycline/minocycline; psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements; any ophthalmologic condition that is clinically unstable; pre-existing skin condition that would prevent adequate evaluations of dermatologic toxicity, as determined by the investigator
- Medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
- Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab, lazertinib, or to tetracyclines, doxycycline, minocycline, timolol*, ruxolitinib*, zinc*, corticosteroids* or their excipients or to any component of the enhanced dermatologic management (*for the amivantamab SC expansion cohorts)
- Participant has received any prior systemic treatment at any time for locally advanced stage III B/C or metastatic stage IV disease (adjuvant or neoadjuvant therapy for stage I, II or IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease)
- Participant has an active or past medical history of leptomeningeal disease
- Sub-study: Participants who have received prior treatment for epidermal growth factor receptor (EGFR)-induced DAEIs with JAK inhibitors (for Cohort A) or calcineurin inhibitors (for Cohort B)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Arm A: Enhanced Dermatologic Management
Participants will receive enhanced dermatologic management to reduce toxicities in skin and nail with doxycycline tablet or minocycline capsule, clindamycin topical lotion, chlorhexidine topical solution, and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with amivantamab intravenously (Dose 1 for body weight [BW] less than 80 kilograms [kg] and Dose 2 for BW greater than or equal to [>=] 80 kg as IV infusion [Arm A]) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1). |
Amivantamab will be administered.
他の名前:
Lazertinib tablet will be administered orally.
他の名前:
Doxycycline tablet will be administered orally. Minocycline capsule will be administered orally. Clindamycin lotion will be used as topical application on the scalp. Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer will be used as topical application. |
|
アクティブコンパレータ:Arm B: Standard-of-Care Dermatologic Management
Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced or metastatic EGFR-mutated NSCLC with amivantamab administered as IV infusion plus lazertinib, dose and dosing schedule as same as experimental arm. |
Amivantamab will be administered.
他の名前:
Lazertinib tablet will be administered orally.
他の名前:
Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer will be used as topical application. |
|
実験的:Sub-study: Cohort A: Ruxolitinib
Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade greater than or equal to [>=] 2, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0) will be enrolled and receive reactive treatment with ruxolitinib in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib. |
Amivantamab will be administered.
他の名前:
Lazertinib tablet will be administered orally.
他の名前:
Doxycycline tablet will be administered orally. Minocycline capsule will be administered orally. Clindamycin lotion will be used as topical application on the scalp. Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer will be used as topical application. Ruxolitinib will be used to the affected skin area. |
|
実験的:Sub-study: Cohort B: Tacrolimus
Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade >= 2, as defined by NCI-CTCAE v5.0) will be enrolled and receive reactive treatment with tacrolimus in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib. |
Amivantamab will be administered.
他の名前:
Lazertinib tablet will be administered orally.
他の名前:
Doxycycline tablet will be administered orally. Minocycline capsule will be administered orally. Clindamycin lotion will be used as topical application on the scalp. Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer will be used as topical application. Tacrolimus will be used as topical application to the affected skin area. |
|
実験的:Amivantamab Subcutaneous (SC) Expansion Cohort: Standard Schedule
Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per standard schedule. If a participant develops a dermatologic adverse event of interest (DAEI) they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1. |
Lazertinib tablet will be administered orally.
他の名前:
Doxycycline tablet will be administered orally. Minocycline capsule will be administered orally. Chlorhexidine solution will be used as topical application on hands and feet. Noncomedogenic skin moisturizer will be used as topical application. Ruxolitinib will be used to the affected skin area. Amivantamab will be administered as SC injection.
他の名前:
Zinc gluconate tablet will be administered. Propranolol tablet will be administered. Timolol will be used to the affected skin area. Clobetasol shampoo will be used on the scalp. |
|
実験的:Amivantamab SC Expansion Cohort: Modified Schedule
Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per modified schedule. If a participant develops a DAEI they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1. |
Lazertinib tablet will be administered orally.
他の名前:
Doxycycline tablet will be administered orally. Minocycline capsule will be administered orally. Amivantamab will be administered as SC injection.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment
時間枠:Up to 12 weeks after initiation of anticancer treatment
|
Number of participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. |
Up to 12 weeks after initiation of anticancer treatment
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants With DAEIs by Severity Based on NCI-CTCAE v 5.0
時間枠:Up to 12 weeks after initiation of anticancer treatment
|
Number of participants with DAEIs by severity based on NCI-CTCAE v 5.0 will be reported. |
Up to 12 weeks after initiation of anticancer treatment
|
|
Number of Participants With Grade >=2 DAEIs Within 6 Months After Initiation of Anticancer Treatment Based on NCI-CTCAE v 5.0
時間枠:Up to 6 months after initiation of anticancer treatment
|
Number of participants with Grade >=2 DAEIs within 6 months after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. |
Up to 6 months after initiation of anticancer treatment
|
|
Number of Grade >= 2 DAEI Per Participants
時間枠:Up to 12 months
|
Number of grade >= 2 DAEI per participants will be reported. |
Up to 12 months
|
|
Time to First Occurrence of Grade >=2 DAEI
時間枠:Up to 12 months
|
Time to first occurrence of Grade >=2 DAEI will be reported. |
Up to 12 months
|
|
Time to Resolution of Grade >= 2 DAEI
時間枠:Up to 12 months
|
Time to resolution of Grade >= 2 DAEI will be reported. |
Up to 12 months
|
|
Number of Participants With Paronychia by Severity Based on NCI-CTCAE v 5.0
時間枠:Up to 6 months after initiation of anticancer treatment
|
Number of participants with paronychia by severity based on NCI-CTCAE v 5.0 will be reported. |
Up to 6 months after initiation of anticancer treatment
|
|
Number of Participants With Scalp Rash by Severity Based on NCI-CTCAE v 5.0
時間枠:Up to 12 months after initiation of anticancer treatment
|
Number of participants with scalp rash by severity based on NCI-CTCAE v 5.0 will be reported. |
Up to 12 months after initiation of anticancer treatment
|
|
Change From Baseline in Skindex Symptoms Domain Score up to 12 Months
時間枠:Baseline, up to Month 12
|
Change from baseline in skindex symptoms domain score up to 12 months will be reported. The score of quality of life will be assessed using the Skindex-16 questionnaire. Skindex-16 is used for participants to rate skin conditions. |
Baseline, up to Month 12
|
|
Change From Baseline in Patient's Global Impression-Severity (PGI-S) Rash up to 12 Months
時間枠:Baseline, up to Month 12
|
Change from baseline in PGI-S rash up to 12 months will be reported. Participant quality of life will be evaluated using PGI-S Rash. PGI-S is a single-item questionnaire assessing participants disease severity on a 7-point response scale. |
Baseline, up to Month 12
|
|
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Score up to 12 Months
時間枠:Baseline, up to Month 12
|
Change from baseline in EORTC-QLQ-C30 score up to 12 months will be reported. EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. |
Baseline, up to Month 12
|
|
Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Patient-reported Outcome (PRO) up to 12 Months (for Amivantamab Subcutaneous Expansion Cohort Only)
時間枠:Baseline, up to Month 12
|
The EQ-5D questionnaire is a brief, generic HRQOL assessment that can that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. EQ-5D scores include EQ-5D valuation index score (a weighted scoring of the 5 dimension scores with a possible range from 0 to 1), EQ-5D visual analog scale (VAS) is a vertical VAS with scores ranging from 0 (worst imaginable health) to 100 (perfect health), and EQ5D descriptive system scores (five scores reflecting each of the 5 EQ-5D health dimensions ranging from 0 [no limitation] to 4 [incapacity]). |
Baseline, up to Month 12
|
|
Percentage of Participants With Dose Reductions, Dose Interruptions, and Dose Discontinuations of Anticancer Treatment due to DAEIs
時間枠:Up to 12 months
|
Percentage of participants with dose reductions, dose interruptions, and dose discontinuations of anticancer treatment due to DAEIs will be reported. |
Up to 12 months
|
|
Relative Dose Intensity (RDI) of Anticancer Treatment
時間枠:Up to 12 months
|
Relative dose intensity of anticancer treatment will be reported. The relative dose intensity is defined as the ratio of total actually received dose versus total prescribed dose. |
Up to 12 months
|
|
Percentage of Participants With Venous Thromboembolism (VTE) Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
時間枠:Up to 12 months
|
Percentage of participants with VTE AEs (pulmonary embolism and deep vein thrombosis) by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to 12 months
|
|
Percentage of Participants With Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
時間枠:Up to 12 months
|
Percentage of participants with AEs by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. |
Up to 12 months
|
|
Progression Free Survival (PFS)
時間枠:Up to 12 months
|
PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first. |
Up to 12 months
|
|
Overall Response Rate (ORR)
時間枠:Up to 12 months
|
ORR is defined as the percentage of participants who achieve a partial response (PR) or better response using RECIST v1.1 as assessed by the investigator. |
Up to 12 months
|
|
Duration of Response (DoR)
時間枠:Up to 12 months
|
DOR will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the RECIST v1.1 response criteria. |
Up to 12 months
|
|
Amivantamab SC Expansion Cohorts: Number of Participants With Grade >= 2 DAEIs Within 12 Weeks After Initiation of Anticancer Treatment
時間枠:Up to 12 weeks after initiation of anticancer treatment
|
Participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. |
Up to 12 weeks after initiation of anticancer treatment
|
|
Amivantamab SC Expansion Cohorts: Percentage of Participants With an Improvement in DAEI After Starting Early Intervention
時間枠:Up to 12 months
|
Percentage of participants showing an improvement in DAEI by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. |
Up to 12 months
|
|
Amivantamab SC Expansion Cohorts: Time to Improvement of DAEIs After Starting Early Intervention
時間枠:Up to 12 months
|
Time to improvement of DAEIs by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event. |
Up to 12 months
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants Achieving Best Response for the Dermatologic Adverse Event
時間枠:Up to 12 weeks
|
Participants achieving best response within 12 weeks of treatment defined as NCI-CTCAE level of the dermatologic adverse event improvement by at least 1 level will be reported. |
Up to 12 weeks
|
協力者と研究者
捜査官
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 気道疾患
- 肺疾患
- 気道腫瘍
- 胸部腫瘍
- 肺新生物
- がん、気管支原性
- 気管支腫瘍
- がん、非小細胞肺
- 硫黄化合物
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- チアゾール
- アゾール
- 炭化水素
- 炭化水素、周期的
- 炭水化物
- ナフタレン
- 多環芳香族炭化水素
- 炭化水素、芳香
- 多環式化合物
- グリコシド
- アミン
- ステロイド
- 融合リング化合物
- ステロイド、フッ素化
- アルコール
- マクロライド
- ラクトン
- ナフテセン
- フェノキシプロパノラミン
- プロパノラミン
- アミノアルコール
- プロパノール
- ピロリジン
- テトラサイクリン
- リンコマイシン
- リンコサミド
- Biguanides
- グアニジン
- アミジン
- チアディアゾール
- モルホリン
- オキサジン
- ベタメタゾン
- ミノサイクリン
- ドキシサイクリン
- タクロリムス
- クロルヘキシジン
- クリンダマイシン
- ティモロール
- プロプラノロール
- クロベタゾール
- アミバンタマブ
- Lazertinib
- ルキソリチニブ
- グルコン酸
その他の研究ID番号
その他の研究ID番号
- 61186372NSC2007
- 61186372NSC2007 (その他の識別子:Janssen Research & Development, LLC)
- 2023-505863-35-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。